This Science News Wire page contains a press release issued by an organization and is provided to you "as is" with little or no review from Science X staff.

Innovation in science

April 15th, 2010

Results of a study presented today at the at the International Liver CongressTM 2010 reveals the effects of a new drug for the treatment of primary biliary cirrhosis, and shows further evaluation is necessary.

INT-747 is a novel derivative of a human bile acid CDCA (that binds to the farnesoid-X receptor). In patients with PBC, addition of INT-747 to UDCA resulted in a significant amelioration of liver enzymes compared to placebo.

PBC is a chronic disease that damages bile ducts. Bile can no longer flow and builds up in the liver instead, damaging the liver cells and causing inflammation and scarring. This eventually leads to cirrhosis.

Provided by European Association for the Study of the Liver

Citation: Innovation in science (2010, April 15) retrieved 20 August 2026 from https://sciencex.com/wire-news/32777908/innovation-in-science.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.